Drug profile · INN
terlipressin acetate
TERLIVAZ
terlipressin acetate (TERLIVAZ) is a vasopressin v1 receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — terlipressin acetate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
terlipressin acetate (TERLIVAZ) is a vasopressin v1 receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Vasopressin V1 receptor binding agent
Primary target: Vasopressin V1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is terlipressin acetate?
terlipressin acetate (TERLIVAZ) is a vasopressin v1 receptor binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for terlipressin acetate?
TERLIVAZ is a marketed brand name for terlipressin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of terlipressin acetate?
terlipressin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.